Magazine Article | March 7, 2018

GSK's Bid To Accelerate Drug Discovery Using AI

Source: Life Science Leader

By Deirdre Coleman, Contributing Writer

GSK’s goal is to transform drug discovery from a slow, sequential, high-failure process into a rapid, integrated, and patient-focused model with the help of tools like artificial intelligence and data. We spoke to Mark Ramsey, chief data officer for R&D (CDO) at GSK, who leads the development and execution of the data strategy for R&D.

The goal of the data strategy is to allow GSK to execute clinical trials more effectively and efficiently, and to accelerate drug discovery. One example of that is an ongoing project to use previously collected clinical trial data as an alternative to a control arm in a study. That could potentially reduce the cost of clinical trials and provide a better experience for patients.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: